»
Annual Reports in Medicinal Chemistry
 
 

Annual Reports in Medicinal Chemistry, 1st Edition

 
Annual Reports in Medicinal Chemistry, 1st Edition,John Macor,ISBN9780123964922
 
 
 

Annual Reports in Medicinal Chemistry

J Macor   

Academic Press

9780123964922

9780123972149

472

229 X 152

Timely and critical reviews of important topics in medicinal chemistry

Print Book + eBook

USD 202.20
USD 337.00

Buy both together and save 40%

Print Book

Paperback

In Stock

Estimated Delivery Time
USD 171.00

eBook
eBook Overview

VST format:

DRM Free included formats: EPub, Mobi, PDF

USD 166.00
Add to Cart
 
 

Key Features

Timely and critical reviews of important topics in medicinal chemistry

Description

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Readership

medicinal, pharmaceutical, and organic chemists

John Macor

Affiliations and Expertise

Neuroscience Discovery Chemistry, Bristol-Myers Squibb, USA

View additional works by John E. Macor

Annual Reports in Medicinal Chemistry, 1st Edition

Personal Essay

  1. Reflections on Medicinal Chemistry at Merck, West Point
  2. Paul S. Anderson

  3. My Path in Seeking New Medicines
  4. Peter R. Bernstein

  5. Tales of Drug Discovery
  6. M. Ross Johnson

    I. Central Nervous System Diseases

    Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts

  7. Recent Developments in Targeting Neuroinflammation in Disease
  8. Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal

  9. Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer’s Disease
  10. Harrie J. M. Gijsen and François P. Bischoff

  11. mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
  12. Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher

  13. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
  14. Kamalesh B. Ruppa, Dalton King and Richard Olson

  15. Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
  16. Lei Zhang and Anabella Villalobos

    II. Cardiovascular and Metabolic Diseases

    Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey

  17. Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
  18. Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler

  19. AMPK Activation in Health and Disease
  20. Iyassu K. Sebhat and Robert W. Myers

  21. Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
  22. Juan C. Jaen, Jay P. Powers and Tim Sullivan

  23. Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
  24. Philip A. Carpino and David Hepworth

    III. Inflammatory Pulmonary and Gastrointestinal Diseases

    Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey

  25. Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
  26. Alaric J. Dyckman

  27. Bifunctional Compounds for the Treatment of COPD
  28. Gary Phillips and Michael Salmon

  29. Inflammatory Targets for the Treatment of Atherosclerosis
  30. Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi

    IV. Oncology

    Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia

  31. Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
  32. Paul F. Richardson

  33. Small-Molecule Antagonists of Bcl-2 Family Proteins
  34. Sean P. Brown and Joshua P. Taygerly

  35. Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
  36. Vibhavari Sail and M. Kyle Hadden

  37. Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
  38. Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda

    V. Infectious Diseases

    Section Editor: John Primeau, Westford, Massachusetts

  39. Recent Advances in the Discovery of Dengue Virus Inhibitors
  40. Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand

  41. Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
  42. Pravin S. Shirude and Shahul Hameed

  43. HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex
  44. Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski

    VI. Topics in Biology

    Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut

  45. Antibody-Drug Conjugates for Targeted Cancer Therapy
  46. Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert

  47. 3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery
  48. Indira Padmalayam and Mark J. Suto

  49. Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?
  50. Nuska Tschammer

  51. Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors
  52. Daniel D. Holsworth and Stefan Krauss

    VII. Topics in Drug Design and Discovery

    Section Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, Pennsylvania

  53. Targeted Covalent Enzyme Inhibitors
  54. Mark C. Noe and Adam M. Gilbert

  55. Drug Design Strategies for GPCR Allosteric Modulators
  56. P. Jeffrey Conn, Scott D. Kuduk and Darío Doller

  57. Progress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for Oncology
  58. Campbell McInnes

    VIII. Trends

    Section Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, Connecticut

  59. New Chemical Entities Entering Phase III Trials in 2011
  60. Gregory T. Notte

  61. To Market, To Market - 2011

    Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg

Quotes and reviews

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." - ENZYMOLOGIA

 
 
Free Shipping
NOTE: We are upgrading our eBook operations; please allow up to 1-2 days for delivery of your eBook order.